TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05847959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chinese medicine prescription：XinKang-I
Description: XK-I will be used in intervention group (20 grams of radix astragalus, 20 grams of radix codonopsis, 10 grams of stir-fried semen lepidii, 8 grams of sweet apricot kernel, 10 grams of cassia twig, 15 grams of poria cocos, 10 grams of atractylodes, 5 grams of honey-roasted licorice, 15 grams of radix et rhizoma salviae miltiorrhizae, 10 grams of chuanxiong rhizoma, 5 grams of tangerine peel).Patients will take XK-I once a day, divided into morning and evening administration. The treatment lasted for 8 weeks.
Study: NCT05220787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cold stored platelets in 100% plasma stored for 10-14 days
Description: Subjects will receive cold stored platelets from the start of surgery until 24 hours after the end of surgery

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Room temperature stored platelets in 100% plasma stored for up to 7 days
Description: Subjects will receive room temperature stored platelets from the start of surgery until 24 hours after the end of surgery
Study: NCT06456827

Intervention type: OTHER
Group type: OTHER
Intervention: Bite force and Gcf
Description: change in bite force will be measured by bite force measuring device at, T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval.~Changes in the following parameters - changes in change in levels of bone turnover markers CTX and BALP using ELISA at T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval

Intervention type: OTHER
Group type: OTHER
Intervention: Bite force and Gcf
Description: change in bite force will be measured by bite force measuring device at, T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval.~Changes in the following parameters - changes in change in levels of bone turnover markers CTX and BALP using ELISA at T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval
Study: NCT06364228

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intranasal spray liquid administration. Oxytocin delivered 2 puffs to each nostril daily for 21 days. The first single dose will be administered at the clinic (visit 1).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin Intranasal Spray 12 International Unit (12IU)
Description: Oxytocin intranasal spray liquid administration. Subjects weighing \< 40 kg will receive 12 IU of oxytocin delivered as 1 puff (6 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (visit 1).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin Intranasal Spray 24 International Unit (24IU)
Description: Oxytocin intranasal spray liquid administration. Subjects weighing \> 40 kg will receive 24 IU of oxytocin delivered as 2 puffs (12 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (visit 1).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Functional MRI
Description: Functional MRI (fMRI) scan with affective Stroop and EmpaTom task (Empathy and Theory of Mind task). fMRI scan will administered pre and post-administration of oxytocin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional MRI
Description: Functional MRI (fMRI) scan with affective Stroop and EmpaTom task (Empathy and Theory of Mind task). fMRI scan will administered pre and post-administration of oxytocin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional MRI
Description: Functional MRI (fMRI) scan with affective Stroop and EmpaTom task (Empathy and Theory of Mind task). fMRI scan will administered pre and post-administration of oxytocin.
Study: NCT04719624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptos®-Si [0.5-1 mm] (bone grafting surgery)
Description: After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptos®-Si [1-2 mm] (bone grafting surgery)
Description: After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
Study: NCT06343727

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Egg white protein pudding
Description: Will consume one egg white protein pudding at the end of their dialysis treatments 3-days per week for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg white protein pudding
Description: Will consume one egg white protein pudding at the end of their dialysis treatments 3-days per week for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: : Ensure Plus
Description: Will consume one Ensure Plus at the end of their dialysis treatments 3-days per week for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: : Ensure Plus
Description: Will consume one Ensure Plus at the end of their dialysis treatments 3-days per week for 12 weeks
Study: NCT05315492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Care Consortium (CCC)
Description: The intervention will train community health workers to take an active role in the drug control and addiction service delivery in the community.
Study: NCT04719624

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Geistlich Bio-Oss (bone grafting surgery)
Description: After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Tooth extraction without bone graft material
Description: After screening and enrollment, subjects will undergo tooth extraction of a single tooth and the socket is filled only by clot. Subject will be followed at 2 weeks, 5 months, and 10 months for healing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptos® (bone grafting surgery)
Description: After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
Study: NCT05368792

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complex Carbohydrate (PREcovery)
Description: Each serving of the complex carbohydrate drink is a clear, colorless, 12.5% maltodextrin drink with a citrus taste, prepared by mixing 54 g of powder (50g carbohydrate) with 400mL of cold water. Participants will consume 2 servings of the complex carbohydrate drink the evening before colonoscopy (100g carbohydrate, 800mL fluid), and 1 serving 2 hours before their colonoscopy (50g carbohydrate, 400mL fluid)
Study: NCT04334187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based addition treatment
Description: The intervention is comprised of 8 weekly group MBAT sessions. Two weekly groups of about 10 participants each will be conducted. All participants will also have the option to receive nicotine patches, gum, or lozenges for four weeks as part of their time in the study. Participants will complete surveys at enrollment (baseline), immediately after their last MBAT session (around 2 months after enrollment) and one month after completing treatment (3 months post-enrollment). Surveys will assess primary and secondary outcomes and satisfaction with the intervention.
Study: NCT06410768

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: multistage shared decision-making program
Description: The multistage shared decision-making program consists of 1) an online patient decision aid; 2) preparatory consult to provide patients with the knowledge and confidence to participate in shared decision-making; and 3) training to improve healthcare professionals' skills for shared decision-making.
Study: NCT05944406

Intervention type: OTHER
Intervention: Educational training of ER Nurses
Description: educational intervention was conducted from 2nd to 5th May 2023 with the triage nurses. This intervention comprised of detailed explanations of how the Triage system is accurately used to categorize the patients presenting in the ED and Triage nurses were instructed to refer non-urgent cases to either the Outpatient department or to the Casualty Medical Officer. The results of the first audit were also shared. Additionally, circulars containing instructions regarding accurate usage of MTS were distributed to all triage nurses
Study: NCT05907109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely monitored parent-mediated hybrid home and clinic based multidisciplinary Early Intervention protocols.
Description: * Parents receive manualized protocols, instructional videos, and toy and material kits to administer EIs at home.~* New modules are provided according to infant age or stage of intervention during the length of brief interventions or 12-months.~* The families will be monitored by clinical researchers weekly. -High risk infants will receive supplemental EI services at the clinic according to developmental needs.~* Infants will receive outcome evaluations within a 42-month follow-up clinic.
Study: NCT06268080

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Depth of anesthesia titration using pEEG
Description: Titration of maintenance anesthetic agent (propofol infusion)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depth of anesthesia titration using pEEG
Description: Titration of maintenance anesthetic agent (propofol infusion)
Study: NCT04798859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family centered in-home rehabilitation
Description: Goal-oriented individualized intervention targeting brain injury related areas noted as challenging by the child and family

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual follow-up in the municipality
Study: NCT05845034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVI + SPEs ablation
Description: electrophysiology substrate mapping is the critical difference between both groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI ablation
Description: electrophysiology substrate mapping is the critical difference between both groups.
Study: NCT04719546

Intervention type: OTHER
Intervention: Observation of related perinatal factors
Description: Data described in Primary outcome measures will be collected in both groups

Intervention type: OTHER
Intervention: Observation of related perinatal factors
Description: Data described in Primary outcome measures will be collected in both groups
Study: NCT05659498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation Program
Description: The standard cardiac rehabilitation program consists of the following: a (1) consultation with a kinesiologist to assess level of fitness and to prepare an individually customized exercise plan, (2) consultation with a dietitian to guide the participant with healthy nutrition choices, (3) on site supervised and/or virtual exercise sessions with gradual elaboration of a home program, (4) weekly educational capsules and monthly workshops related to cardiac health, and, (5) if deemed necessary by the treating team, consultation with a psychologist, an occupational therapist, a physiotherapist, or a social worker.
Study: NCT06514339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: shenhuang granule
Description: Traditional Chinese medicine compound Shenhuang Granules is developed by Professor Fang Bangjiang, a scholar in the team of Qi-Huang, which is composed of ginseng, rhubarb, dandelion, etc., with the effect of Fuzheng Guben, clearing heat and detoxification, promoting qi and promoting blood and detumification.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: Placebo was provided by Tianjin Hongri Pharmaceutical Co., LTD., and was given orally or nasally (through gastric tube or intestinal tube) after dissolution of 100ml warm water (temperature about 40°) in 1 package twice a day.
Study: NCT06515275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education via video (QR code links)
Description: Video education on self-administered medications for women undergoing IVF treatment
Study: NCT04753515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine combined with midazolam and remifentanil.
Description: Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.5 mcg/kg dexmedetomidine over 5 min via separate syringe pumps.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol combined with midazolam and remifentanil.
Description: Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.33 mg/kg propoful over 5 min via separate syringe pumps.
Study: NCT04556175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Health
Description: Motivational interviewing for mothers pre-and postpartum; fluoride varnish for infants/children.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle
Description: Didactic maternal and child health educational sessions for mothers pre-and postpartum; fluoride varnish for infants/children.
Study: NCT05556252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogenated water consumption
Description: Participants will start consuming hydrogenated water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml hydrogenated water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) hydrogenated water in total. In this way, participants will be provided with hydrogenated water for three cycles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Drinking water consumption
Description: Participants will start consuming drinking water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml drinking water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) drinking water in total. In this way, participants will be provided with drinking water for three cycles.
Study: NCT06284473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine is an N-methyl-D aspartate receptor agonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intranasal saline flushes pollen, dust, and other debris from nasal passages. It also removes excess mucus and adds moisture
Study: NCT05681988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early minimally invasive image guided endoscopic hematoma evacuation
Description: The intervention group will first receive BMT (as defined below) upon admission and early minimally invasive image guided endoscopic hematoma evacuation as an add-on therapy to BMT. Surgery will be performed within 6-24 hours after SSICH symptom onset. Surgery will be performed in an emergency operating theatre or a hybrid operation theatre equipped with intraoperative CT (in hybrid OR), neuronavigation, and neuro-endoscopy.The position and progress of the trocar towards the hematoma cavity will be monitored with neuro-navigation. The endoscope (LOTTA® system, Karl Storz Endoscopes, Germany; Minop®, BBraun, Tuttlingen, Germany or equivalent) will be inserted into the trocar and tracked using neuro-navigation. Using the pre-planned trajectory, the hematoma will be entered. Using continuous suction and irrigation, the hematoma will be aspirated and/or washed out.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment (BMT)
Description: The control group will receive the current gold standard treatment for SSICH according to the guidelines (BMT). This involves strict blood pressure control (SBP\<140mmHg), if needed with intravenous or intraarterial blood pressure lowering agents, reversal of anticoagulation if applicable, intensive care surveillance and nursing on a ICU or stroke unit, control of seizures as well as glucose levels as needed and neurointensive monitoring if deemed necessary

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Best medical treatment (BMT)
Description: The control group will receive the current gold standard treatment for SSICH according to the guidelines (BMT). This involves strict blood pressure control (SBP\<140mmHg), if needed with intravenous or intraarterial blood pressure lowering agents, reversal of anticoagulation if applicable, intensive care surveillance and nursing on a ICU or stroke unit, control of seizures as well as glucose levels as needed and neurointensive monitoring if deemed necessary
Study: NCT05222308

Intervention type: OTHER
Group type: OTHER
Intervention: Post-Mortem Plan
Description: Following the death of the terminally ill participant, investigators will work with networks as the wishes of the deceased are executed. Continued engagement at this point will allow us to provide support to the network during a difficult period or time while also identifying shortcomings in our plans and systemic challenges to postmortem planning. Working with those who are grieving is a delicate proposition, but one with which my students and I have extensive experience.
Study: NCT05347251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervicothoracic mobility program
Description: Participants in this group will receive mobilization at a cervical and thoracic level along with conventional physical therapy protocol like Hot packs and exercise therapy.~At the cervical, PA glides (central) and transverse glides will be given for mobilization.~At thoracic, PA glides (central) and transverse glides will be given for mobilization.~Exercise therapy includes stretching and strengthening both cervical and thoracic muscles. At the cervical level, neck isometric (flexion, extension, side bending) will be given to patients to enhance strengthening, and neck~stretching exercises (flexors, extensors, side benders~and rotators) will perform as well. Similarly, at the thoracic~level, strengthening and stretching of thoracic muscle will be performed

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Treatment
Description: It will be the control group. The participants who will be allocated in this group receive the only conventional physical therapy protocol (Hot pack and exercise therapy). Exercise therapy includes stretching and strengthening of neck and upper back muscles. At the cervical level, neck isometric (flexion, extension, side bending) will be given to patients to enhance strengthening, and neck stretching exercises (flexors,~extensors, side benders, and rotators) will perform~as well. Similarly at the thoracic level, strengthening and stretching of thoracic muscle will be performed.
Study: NCT05787665

Intervention type: OTHER
Intervention: phone call at 3 months
Description: patients will be called at 3 months to know if they are alive and to know if they have been rehospitalized

Intervention type: OTHER
Intervention: phone call at 3 months
Description: patients will be called at 3 months to know if they are alive and to know if they have been rehospitalized
Study: NCT04832932

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccines
Description: Emergency-use authorized COVID-19 vaccines

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccines
Description: Emergency-use authorized COVID-19 vaccines

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccines
Description: Emergency-use authorized COVID-19 vaccines

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccines
Description: Emergency-use authorized COVID-19 vaccines

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccines
Description: Emergency-use authorized COVID-19 vaccines

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccines
Description: Emergency-use authorized COVID-19 vaccines
Study: NCT04701333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline 1 MG
Description: Dopamine agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05266612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG2025
Description: 1. 1.0×108PFU Day 1 and 15~2. 2.0×108PFU Day 1 and 15~3. 3.0×108PFU Day 1 and 15~4. 4.0×108PFU Day 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG2025
Description: 1. 1.0×108PFU Day 1 and 15~2. 2.0×108PFU Day 1 and 15~3. 3.0×108PFU Day 1 and 15~4. 4.0×108PFU Day 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Flat dose of 240 mg every two weeks.
Study: NCT05354908

Intervention type: OTHER
Intervention: scientific and academic productivity
Description: Number and quartile of scientific products generated by the group
Study: NCT05081531

Intervention type: RADIATION
Group type: OTHER
Intervention: Adaptive Radiotherapy
Description: All the patients will be treated with VMAT technique in its RapidArc form. A simultaneous integrated boost (SIB) technique will be used. The GTV will encompass the tumor delineated on CT scan, adjusted for MRI and PET scans. Patients will be treated with a total dose of 66 Gy, 60 Gy and 54 Gy on PTV1, PTV2 and PTV3, respectively, delivered in 30 fractions, 5 fractions per week.